|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
(5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one |
International Nonproprietary Names ![]() |
|
INN number | INN |
9150 | ponesimod |
Synonyms ![]() |
ACT-128800 | ACT128800 | Compound 8bo [PMID:20446681] |
Database Links ![]() |
|
CAS Registry No. | 854107-55-4 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL1096146 |
GtoPdb PubChem SID | 318164839 |
PubChem CID | 11363176 |
Search Google for chemical match using the InChIKey | LPAUOXUZGSBGDU-ULCCENQXSA-N |
Search Google for chemicals with the same backbone | LPAUOXUZGSBGDU |
Search PubMed clinical trials | ponesimod |
Search PubMed titles | ponesimod |
Search PubMed titles/abstracts | ponesimod |
Search UniChem for chemical match using the InChIKey | LPAUOXUZGSBGDU-ULCCENQXSA-N |
Search UniChem for chemicals with the same backbone | LPAUOXUZGSBGDU |
Comments |
Ponesimod (ACT-128800) is an orally active sphingosine-1-phosphate (S1P) receptor modulator [1] in development as a disease-modifying therapy (DMT) for multiple sclerosis (MS). The compound is reported as a partial S1P4 and S1P5 receptor agonist, with maximum activity 18% and 42% of that induced by the endogenous ligand S1P (at 10μM ACT-128800) [1]. The INN record for ponesimod stipulates the (2R) stereoisomer ((2Z,5Z)-5-{3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenylmethylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one). Selective SIP1 receptor agonists are being developed and investigated for immunomodulatory/immunosuppresant potential in autoimmune diseases. |